TARS insider buying and SEC filings, explained
Tarsus Pharmaceuticals, Inc. · CIK 1819790
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Biological Products, (No Diagnostic Substances)
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$8.1M
Planned sales (10b5-1)
$11.8M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 15, 2026 | Planned (10b5-1) | William J. Phd Link (Director) sold 12,500 shares at about $78.38 ($980K), marked as a 10b5-1 plan trade. Holdings down 12% to 94,487 shares. | SEC filing Filed Sep 17, 2026 |
| Sep 4, 2026 | Planned (10b5-1) | Elizabeth Yeu Lin (Chief Medical Officer) sold 13,953 shares directly and indirectly (by spouse) at about $87.50 ($1.2M), marked as a 10b5-1 plan trade. Direct holdings down 81% to 2,547 shares. | SEC filing Filed Sep 9, 2026 |
| Sep 4, 2026 | Planned (10b5-1) | Bobak R. Azamian (CEO and Director) sold 10,000 shares indirectly (by trust) at about $90.56 ($906K), marked as a 10b5-1 plan trade. Holdings by trust down 1% to 827,991 shares. | SEC filing Filed Sep 9, 2026 |
| Sep 4, 2026 | Planned (10b5-1) | Seshadri Neervannan (President / COO) sold 4,564 shares at $85.00 ($388K), marked as a 10b5-1 plan trade. Holdings down 5% to 78,532 shares. | SEC filing Filed Sep 9, 2026 |
| Sep 2, 2026 | Planned (10b5-1) | Bobak R. Azamian (CEO and Director) sold 10,000 shares indirectly (by trust) at about $80.06 ($801K), marked as a 10b5-1 plan trade. Holdings by trust down 1% to 837,991 shares. | SEC filing Filed Sep 3, 2026 |
| Sep 1–2, 2026 | Planned (10b5-1) | Elizabeth Yeu Lin (Chief Medical Officer) sold 11,578 shares directly and indirectly (by spouse) between Sep 1 and Sep 2 at about $77.56 ($898K), marked as a 10b5-1 plan trade. Direct holdings down 43% to 13,320 shares. | SEC filing Filed Sep 3, 2026 |
| Jun 17, 2026 | Planned (10b5-1) | Bobak R. Azamian (CEO and Director) sold 10,000 shares indirectly (by trust) at about $61.55 ($615K), marked as a 10b5-1 plan trade. Holdings by trust down 1% to 847,991 shares. | SEC filing Filed Jun 22, 2026 |
| Jun 15, 2026 | Planned (10b5-1) | Katherine Goodrich (Director) sold 2,954 shares at $62.08 ($183K), marked as a 10b5-1 plan trade. Holdings down 57% to 2,233 shares. | SEC filing Filed Jun 17, 2026 |
| Jun 16, 2026 | Sale | Jeffrey S Farrow (CFO) sold 14,396 shares at $60.95 ($877K). Holdings down 20% to 56,801 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jun 17, 2026 |
| Jun 15, 2026 | Planned (10b5-1) | William J. Phd Link (Director) sold 12,500 shares at about $62.12 ($776K), marked as a 10b5-1 plan trade. Holdings down 10% to 106,786 shares. | SEC filing Filed Jun 17, 2026 |
| Mar 20, 2026 | Planned (10b5-1) | Seshadri Neervannan (President / COO) sold 2,989 shares at $66.75 ($200K), marked as a 10b5-1 plan trade. Holdings down 3% to 82,791 shares. | SEC filing Filed Mar 24, 2026 |
| Mar 17–19, 2026 | Sale | Elizabeth Yeu Lin (Chief Medical Officer) sold 1,144 shares between Mar 17 and Mar 19 at about $68.36 ($78K). Holdings down 5% to 23,308 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 19, 2026 |
| Mar 17–19, 2026 | Sale | Bryan Wahl (General Counsel) sold 12,440 shares between Mar 17 and Mar 19 at about $68.36 ($850K). Holdings down 16% to 63,959 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 19, 2026 |
| Mar 17–19, 2026 | Sale | Dianne C. Whitfield (Chief Human Resources Officer) sold 12,274 shares between Mar 17 and Mar 19 at about $68.36 ($839K). Holdings down 26% to 35,028 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 19, 2026 |
| Mar 17–19, 2026 | Sale | Bobak R. Azamian (CEO and Director) sold 34,603 shares between Mar 17 and Mar 19 at about $68.34 ($2.4M). Holdings down 51% to 33,421 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 19, 2026 |
| Mar 17–19, 2026 | Sale | Seshadri Neervannan (President / COO) sold 11,324 shares between Mar 17 and Mar 19 at about $68.21 ($772K). Holdings down 12% to 85,780 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 19, 2026 |
| Mar 17–19, 2026 | Sale | Aziz Mottiwala (Chief Commercial Officer) sold 13,056 shares between Mar 17 and Mar 19 at about $68.36 ($893K). Holdings down 18% to 61,480 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 19, 2026 |
| Mar 17–19, 2026 | Sale | Jeffrey S Farrow (CFO) sold 6,430 shares between Mar 17 and Mar 19 at about $68.36 ($440K). Holdings down 13% to 43,316 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 19, 2026 |
| Mar 16, 2026 | Planned (10b5-1) | William J. Phd Link (Director) sold 12,500 shares at about $68.79 ($860K), marked as a 10b5-1 plan trade. Holdings down 10% to 116,332 shares. | SEC filing Filed Mar 18, 2026 |
| Mar 4, 2026 | Planned (10b5-1) | Seshadri Neervannan (President / COO) sold 8,366 shares at $76.67 ($641K), marked as a 10b5-1 plan trade. Holdings down 11% to 70,817 shares. | SEC filing Filed Mar 5, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Dianne C. Whitfield (Chief Human Resources Officer) sold 15,565 shares at about $80.67 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 40% to 23,393 shares. | SEC filing Filed Jan 6, 2026 |
| Dec 24, 2025 | Planned (10b5-1) | Bobak R. Azamian (CEO and Director) sold 6,000 shares indirectly (by trust) at about $82.51 ($495K), marked as a 10b5-1 plan trade. Holdings by trust down 1% to 857,991 shares. | SEC filing Filed Dec 30, 2025 |
| Dec 16, 2025 | Planned (10b5-1) | Dianne C. Whitfield (Chief Human Resources Officer) sold 7,397 shares at $80.10 ($592K), marked as a 10b5-1 plan trade. Holdings down 16% to 38,958 shares. | SEC filing Filed Dec 18, 2025 |
| Dec 16, 2025 | Sale | Elizabeth Yeu Lin (Chief Medical Officer) sold 2,078 shares at $79.50 ($165K). Holdings down 9% to 21,941 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 17, 2025 |
| Dec 15, 2025 | Planned (10b5-1) | William J. Phd Link (Director) sold 12,500 shares at about $81.43 ($1.0M), marked as a 10b5-1 plan trade. Holdings down 9% to 128,832 shares. | SEC filing Filed Dec 17, 2025 |
| Dec 15, 2025 | Sale | William J. Phd Link (Director) sold 10,446 shares indirectly (by entity) at about $81.07 ($847K). Holdings by entity down 100% to 0 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 17, 2025 |
37 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 3, 2026, 4:06 PM ET 8-K | Earnings released (Item 2.02) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow TARS in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.